What the safety record actually shows

The headline figure from the manufacturer's most recent safety review is straightforward: no serious adverse device effects (SADEs) were reported across any of the clinical studies compiled in ChondroFiller® liquid's Clinical Evaluation Report (CER) Version 09, dated April 2025. That review draws on a post-market surveillance dataset covering more than 19,400 treated cases across all joints, with the knee the most extensively documented.

The device-related complication rate reported in the CER sits at approximately 0%. Reoperation rates in knee-specific studies fall in the range of 3–8% — meaning that in the large majority of cases, no further procedure was needed following treatment.

Two points of context matter here. First, the CER is a formal regulatory document — a manufacturer's obligation under CE Class III device rules — rather than a marketing claim. It is independently audited as part of the certification process. Second, and equally important: this evidence is manufacturer-compiled and manufacturer-sponsored. No independent registry or external systematic review has yet replicated these figures in isolation. The safety record should therefore be read as 'no serious complications reported in the available clinical evidence' rather than as a guarantee of zero risk. With that framing in place, the picture is nonetheless consistently reassuring across more than a decade of post-market data accumulation, as reflected in this ninth iteration of the CER.

How the risk compares to surgical cartilage repair

Placed alongside the established surgical alternatives, those reoperation figures carry more weight. For context, published data cited in the CER show that ACI/MACI — a two-stage surgical procedure in which cartilage cells are harvested, cultured in a laboratory, and then reimplanted — carries a complication rate of up to 17% and a reoperation rate of up to 37%, roughly one in three cases. Microfracture, the most widely performed cartilage surgery, fares similarly on retreatment: reoperation rates in the comparative literature reach up to 41%, more than four in ten patients.

ChondroFiller®'s 3–8% reoperation rate sits well below both benchmarks. The honest caveat is that a direct head-to-head randomised controlled trial comparing these complication profiles has not been conducted, so the comparison is drawn from separate datasets rather than a single controlled study.

Functional and imaging data provide an indirect line of reassurance. Across four knee-specific studies, patients showed a mean improvement of approximately 30 points on the IKDC score — a 100-point patient-reported measure of knee function, where higher scores indicate better function and 30 points represents roughly the difference between significant disability and near-normal activity. MRI MOCART scores, which grade defect fill on a 100-point scale, ranged from 81.6 to 84.3 in European knee studies, indicating that more than 80% of the defect was filled with repair tissue. Improvements of that magnitude, sustained over follow-up without reported adverse reactions, suggest the collagen scaffold is not provoking clinically meaningful host tissue responses.

Murine collagen and immune reaction risk

ChondroFiller® is derived from murine — mouse — Type I collagen, which makes it a xenogeneic material: it originates from a different species. For many patients, that is the first question once they understand the product's biological origin, and it deserves a direct answer.

The mechanism of action shapes the immunogenic risk profile considerably. The scaffold is acellular — it contains no donor cells, only the structural collagen matrix. Cell-surface antigens are the principal trigger for a foreign-body immune response; an acellular scaffold removes that primary stimulus. The collagen is acid-extracted and purified before use, which further reduces the antigen load reaching the joint.

Across the clinical studies reviewed in the manufacturer's CER, no allergic or immune-mediated adverse events were reported — a pattern consistent across the same post-market dataset that underpins the overall safety figures described in the preceding sections. That consistent absence of immune events aligns with the acellular design: once the material gels in situ within minutes of injection, it acts as a temporary structural framework. The patient's own progenitor cells migrate in and initiate acellular matrix-induced chondrogenesis — the body's own biological process of tissue building — while the scaffold progressively biodegrades and is replaced.

Sensitivity screening is part of clinical patient selection, meaning patients with a known collagen hypersensitivity are identified and excluded before treatment. This is standard risk management rather than a signal that reactions are common.

Why the injection route carries lower procedural risk

The delivery route itself is a meaningful part of the procedural risk picture. ChondroFiller® is administered as an ultrasound-guided injection in an outpatient clinic setting — no general anaesthetic, no theatre admission, no surgical incision. The scaffold material is placed directly into the defect under image guidance, and the patient remains fully mobile on the day of treatment.

Intra-articular injections carry their own procedural risks — principally infection and haematoma — but these are materially lower than those associated with arthroscopic or open cartilage surgery, which bring the compounding hazards of general or spinal anaesthesia, wound management, and the inflammatory burden of a surgically opened joint. The UK injection protocol addresses the infection risk directly: IV antibiotic prophylaxis is given as part of the standard treatment package.

Avoiding theatre admission also removes the extended post-operative recovery that follows cartilage surgery. Microfracture and ACI/MACI typically require weeks of restricted weight-bearing before function is gradually restored. The outpatient injection pathway does not carry that recovery burden — a practical difference for patients as much as a clinical one. Note that external clinical literature also describes arthroscopic delivery of ChondroFiller®, but that surgical route is a separate pathway from the current injectable service.

Which knees are suitable — and which are not

Good outcomes with ChondroFiller® depend heavily on choosing the right patient before treatment begins — patient selection is, in effect, the primary safety filter.

The core regenerative indication is a focal chondral or osteochondral defect of up to 6 cm², in a knee that is mechanically stable. In practice this means a localised area of cartilage damage — typically from an acute injury, osteochondritis dissecans (OCD), or the cartilage loss that can follow meniscal injury — rather than the diffuse, joint-wide wear of advanced osteoarthritis. Structural stability matters: the collagen scaffold gels within minutes of injection and needs a stable mechanical environment to allow the patient's own progenitor cells to migrate in and begin repair.

Three contraindications carry particular weight in the regenerative pathway: untreated ligament instability, significant limb malalignment, and end-stage diffuse osteoarthritis. Each undermines the scaffold mechanically rather than biologically — abnormal load distribution or joint instability prevents the repair tissue from maturing correctly, regardless of how well the scaffold itself performs.

The injectable form extends use to patients with more advanced, diffuse knee wear — Kellgren-Lawrence Grade III or IV — in an additive, cushioning role. The expectation there is symptom relief and joint protection rather than focal cartilage regeneration, and patients should be counselled accordingly.

Pre-treatment MRI is central to candidate identification: it characterises defect size, depth, surrounding bone integrity, and the condition of adjacent cartilage — the information a clinician needs to judge whether the regenerative indication genuinely applies or whether a different pathway would serve the patient better.

What the evidence cannot yet confirm

The 19,400+ case figure underpinning the safety record spans all joints — knee, hip, ankle, and others. CER Version 09 (April 2025) does not isolate a dedicated knee adverse-event count from that total, so the headline rate reflects a cross-joint pool rather than a knee-specific registry. That aggregation is worth holding in mind when contextualising the numbers.

The data are manufacturer-compiled, as is standard for CE-marked Class III devices under EU Medical Device Regulation, which requires continuous CER maintenance. Version 09 is the ninth iteration of a living document — that reflects ongoing post-market surveillance rather than any deficiency in the process. What it is not is an independent adverse-event database or a purpose-designed trial measuring complication incidence as a primary endpoint. Those structures — a multicentre knee registry stratified by defect size and follow-up duration, and a randomised controlled trial with safety as its registered endpoint — represent the form of independent verification that longer-established surgical procedures have had decades to accumulate.

For patients weighing these points, the outstanding questions are structural rather than numerical. A dedicated knee registry or a head-to-head trial would add precision — but the consistency of the reported direction across nine CER versions and four knee-specific studies is itself evidence worth placing on the scales.